{"title":"Common blood pressure treatments lower the risk of major cardiovascular events","authors":"Flávio Danni Fuchs MD, PhD (Commentary Author)","doi":"10.1016/j.ehbc.2004.03.018","DOIUrl":null,"url":null,"abstract":"<div><h3>Question</h3><p>What are the effects of different blood pressure lowering regimens on major cardiovascular events?</p></div><div><h3>Study design</h3><p>Prospectively designed meta-analysis of randomised controlled trials.</p></div><div><h3>Main results</h3><p>Twenty-nine RCTs with 2 to 8.4 years follow up were included in the analysis. ACE inhibitors, calcium antagonists or angiotensin-receptor blockers for high blood pressure significantly reduce the risk of major cardiovascular events compared with placebo or control (see Table 1). Setting a lower target blood pressure for treatment significantly reduces the risk of major cardiovascular events compared with setting a higher treatment target. There was no significant difference in the risk of major cardiovascular events among ACE inhibitor, calcium antagonist or diuretic/β-blocker-based treatment regimens. In general, a greater reduction of blood pressure resulted in a greater reduction in the risk of major cardiovascular events.<span><div><div><table><tbody><tr><td><strong>Table 1</strong> Effects of different treatment regimens on blood pressure and major cardiovascular risk</td></tr><tr><td>Treatment regimen</td><td>No. of RCTs</td><td>Weighted mean difference in blood pressure (SBP/DBP)(mmHg)</td><td>RR for major cardiovascular events (95% CI)</td></tr><tr><td>Angiotensin converting enzyme inhibitors vs placebo</td><td>5</td><td>−5/−2</td><td>0.78 (0.73 to 0.83)</td></tr><tr><td>Calcium antagonist vs placebo</td><td>3</td><td>−8/−4</td><td>0.82 (0.71 to 0.95)</td></tr><tr><td>Angiotensin receptor blocker vs control*</td><td>4</td><td>−2/−1</td><td>0.90 (0.83 to 0.96)</td></tr><tr><td>Angiotensin receptor blocker vs calcium antagonist</td><td>5</td><td>+1/+1</td><td>0.97 (0.92 to 1.03)</td></tr><tr><td>Angiotensin converting enzyme inhibitor vs diuretic or β blocker</td><td>6</td><td>+2/0</td><td>1.02 (0.98 to 1.07)</td></tr><tr><td>Calcium antagonist regimens vs diuretic or β blocker</td><td>9</td><td>+1/+1</td><td>1.04 (1.00 to 1.09)</td></tr><tr><td>Lower vs higher target blood pressure</td><td>4</td><td>−4/−3</td><td>0.85 (0.76 to 0.95)</td></tr><tr><td>*The comparison pooled trials where either some or all people in the non-angiotensin-receptor blocker group received active treatment.</td></tr></tbody></table></div></div></span></p></div><div><h3>Authors’ conclusions</h3><p>All widely used blood pressure lowering treatments reduce the risk of major cardiovascular events. A greater reduction in blood pressure leads to a greater reduction in the risk of major cardiovascular events.</p></div>","PeriodicalId":100512,"journal":{"name":"Evidence-based Healthcare","volume":"8 3","pages":"Pages 153-155"},"PeriodicalIF":0.0000,"publicationDate":"2004-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ehbc.2004.03.018","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence-based Healthcare","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1462941004000531","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Question
What are the effects of different blood pressure lowering regimens on major cardiovascular events?
Study design
Prospectively designed meta-analysis of randomised controlled trials.
Main results
Twenty-nine RCTs with 2 to 8.4 years follow up were included in the analysis. ACE inhibitors, calcium antagonists or angiotensin-receptor blockers for high blood pressure significantly reduce the risk of major cardiovascular events compared with placebo or control (see Table 1). Setting a lower target blood pressure for treatment significantly reduces the risk of major cardiovascular events compared with setting a higher treatment target. There was no significant difference in the risk of major cardiovascular events among ACE inhibitor, calcium antagonist or diuretic/β-blocker-based treatment regimens. In general, a greater reduction of blood pressure resulted in a greater reduction in the risk of major cardiovascular events.
Table 1 Effects of different treatment regimens on blood pressure and major cardiovascular risk
Treatment regimen
No. of RCTs
Weighted mean difference in blood pressure (SBP/DBP)(mmHg)
RR for major cardiovascular events (95% CI)
Angiotensin converting enzyme inhibitors vs placebo
5
−5/−2
0.78 (0.73 to 0.83)
Calcium antagonist vs placebo
3
−8/−4
0.82 (0.71 to 0.95)
Angiotensin receptor blocker vs control*
4
−2/−1
0.90 (0.83 to 0.96)
Angiotensin receptor blocker vs calcium antagonist
5
+1/+1
0.97 (0.92 to 1.03)
Angiotensin converting enzyme inhibitor vs diuretic or β blocker
6
+2/0
1.02 (0.98 to 1.07)
Calcium antagonist regimens vs diuretic or β blocker
9
+1/+1
1.04 (1.00 to 1.09)
Lower vs higher target blood pressure
4
−4/−3
0.85 (0.76 to 0.95)
*The comparison pooled trials where either some or all people in the non-angiotensin-receptor blocker group received active treatment.
Authors’ conclusions
All widely used blood pressure lowering treatments reduce the risk of major cardiovascular events. A greater reduction in blood pressure leads to a greater reduction in the risk of major cardiovascular events.